Drug
D1072 | proscillaridin
C
C01AB51 Proscillaridin, combinations
[C01AB] Scilla glycosides
[C01A] CARDIAC GLYCOSIDES
[C01] CARDIAC THERAPY
[C] Cardiovascular system
C01AB01 Proscillaridin
[C01AB] Scilla glycosides
[C01A] CARDIAC GLYCOSIDES
[C01] CARDIAC THERAPY
[C] Cardiovascular system
| Toxicity | Dose | Time | Species | Model | Method | Action | Positive criterion | Reference |
|---|---|---|---|---|---|---|---|---|
| MEMBRANE POTENTIAL | 0.09±0.02 | human | qHTS-HepG2 | MMP assay | decrease | IC50 | 163 | |
| MEMBRANE POTENTIAL | 0.07 | human | HepG2 | MMP assay | decrease | IC50 | 163 | |
| MEMBRANE POTENTIAL | rat | hepatocytes | MMP assay | Negative | IC50 | 163 | ||
| Pictogram | Signal | Statements | Precautionary Statement Codes |
|---|---|---|---|
 |
Danger |
Aggregated GHS information provided by 40 companies from 2 notifications to the ECHA C&L Inventory. H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral] Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. |
P264, P270, P301+P310, P321, P330, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.) |
| Organism | Test type | Route | Dose (normalized dose) | Effect | Source |
|---|---|---|---|---|---|
| cat | LD50 | intraduodenal | 268ug/kg (0.268mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 14, Pg. 716, 1964. | |
| guinea pig | LD50 | oral | 6810ug/kg (6.81mg/kg) | United States Patent Document. Vol. #4230702, | |
| mouse | LD50 | intravenous | 4700ug/kg (4.7mg/kg) | Oyo Yakuri. Pharmacometrics. Vol. 2, Pg. 411, 1968. | |
| rat | LD50 | intravenous | 9mg/kg (9mg/kg) | Toxicology and Applied Pharmacology. Vol. 20, Pg. 599, 1971. | |
| rat | LD50 | subcutaneous | > 1gm/kg (1000mg/kg) | Oyo Yakuri. Pharmacometrics. Vol. 2, Pg. 411, 1968. | |
| cat | LDLo | parenteral | 1mg/kg (1mg/kg) | Acta Poloniae Pharmaceutica. For English translation, see APPFAR. Vol. 34, Pg. 431, 1977. | |
| mouse | LD50 | oral | 30500ug/kg (30.5mg/kg) | Drugs in Japan Vol. 6, Pg. 723, 1982. | |
| rat | LD50 | oral | 56mg/kg (56mg/kg) | Toxicology and Applied Pharmacology. Vol. 20, Pg. 599, 1971. | |
| cat | LD50 | oral | 377ug/kg (0.377mg/kg) | behavioral: convulsions or effect on seizure threshold | Arzneimittel-Forschung. Drug Research. Vol. 20, Pg. 1, 1970. |
| bird - domestic | LD50 | intravenous | 124ug/kg (0.124mg/kg) | Nippon Yakurigaku Zasshi. Japanese Journal of Pharmacology. Vol. 62(3), Pg. 195S, 1966. | |
| guinea pig | LD50 | intravenous | 280ug/kg (0.28mg/kg) | behavioral: convulsions or effect on seizure threshold | Arzneimittel-Forschung. Drug Research. Vol. 20, Pg. 1, 1970. |
| bird - domestic | LD50 | oral | 373ug/kg (0.373mg/kg) | Nippon Yakurigaku Zasshi. Japanese Journal of Pharmacology. Vol. 62(3), Pg. 195S, 1966. | |
| cat | LD50 | intravenous | 111ug/kg (0.111mg/kg) | behavioral: convulsions or effect on seizure threshold | Arzneimittel-Forschung. Drug Research. Vol. 20, Pg. 1, 1970. |
| ((6-Deoxy-alpha-L-mannopyranosyl)oxy)-14-hydroxybufa-4,20,22-trienolide | (3beta)-3-[(6-deoxy-alpha-L-mannopyranosyl)oxy]-14-hydroxybufa-4,20,22-trienolide | 14-Hydroxy-3-beta-(rhamnosyloxy)bufa-4,20,22-trienolide |
| 14-Hydroxy-3beta-(rhamnosyloxy)bufa-4,20,22-trienolide | 3-beta,14-beta-Dihydroxybufa-4,20,22-trienolide 3-rhamnoside | 3-beta-((6-Deoxy-alpha-L-mannopyranosyl)oxy)-14-hydroxybufa-4,20,22-trienolide |
| 3-beta-Rhamnosido-14-beta-hydroxy-delta(sup 4,20,22)-bufatrienolide | 466-06-8 | A-32686 |
| API0015855 | Bufa-4,20,22-trienolide, 3-((6-deoxy-alpha-L-mannopyranosyl)oxy)-14-hydroxy-, (3-beta)- | Bufa-4,20,22-trienolide, 3-((6-deoxy-alpha-L-mannopyranosyl)oxy)-14-hydroxy-, (3beta)- |
| Bufa-4,20,22-trienolide, 3-beta-((6-deoxy-alpha-L-mannosyl)oxy)-14-hydroxy- | C12816 | CAS-466-06-8 |
| CCG-220986 | CHEBI:32065 | CHEMBL600325 |
| CS-0021123 | Caradrin | Caradrine |
| Cardion | Cardiovite | Carmazon |
| Coratol | DB13307 | DSSTox_CID_3532 |
| DSSTox_GSID_23532 | DSSTox_RID_77066 | DTXSID5023532 |
| Desgluco-transvaalin | EINECS 207-370-4 | HMS3715E13 |
| HY-N2331 | Herzo | Herzo proscillan |
| KC6BL281EN | MYEJFUXQJGHEQK-ALRJYLEOSA-N | NCGC00016447-01 |
| NCGC00344555-01 | NSC 7521 | PSC-801 |
| Procardin | Procilan | Proscilardyna |
| Proscilardyna [Polish] | Proscilaridina | Proscilaridina [INN-Spanish] |
| Proscillan | Proscillaridin (JAN/USAN/INN) | Proscillaridin A |
| Proscillaridin [USAN:INN:BAN:JAN] | Proscillaridina | Proscillaridina [DCIT] |
| Proscillaridine | Proscillaridine A | Proscillaridine [INN-French] |
| Proscillaridinum | Proscillaridinum [INN-Latin] | Proslladin |
| Prostosin | Proszin | Protasin |
| Purosin-TC | Q7250550; | Rhamnopyranoside, scillarenin-3, alpha-L- |
| SCHEMBL123759 | Sandoscill | Scilla didier |
| Scillacrist | Scillarenin 3-beta-rhamnoside | Scillarenin 3beta-rhamnoside |
| Scillarenin, 3-alpha-L-rhamnopyranoside | Scillarenin, 3alpha-L-rhamnopyranoside | Scillarenin-rhamnose |
| Scillarenin-rhamnose [German] | Simeon | Solestril |
| Stellarid | Talucard | Talusin |
| Talusin (TN) | Tox21_110442 | Tox21_110442_1 |
| Tradenal | Transvaalin, degluco- | UNII-KC6BL281EN |
| Urgilan | Wirnesin | ZINC8214665 |
| proscillaridin |